Delving into the Latest Updates on PPI-4667 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

S1PR1

Action

agonists

Mechanism

S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists)

Therapeutic Areas

Immune System Diseases

Active Indication-

Inactive Indication

Autoimmune Diseases

Originator Organization

Praecis Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Praecis Pharmaceuticals, Inc.

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modifications to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia.

100 Deals associated with PPI-4667

Login to view more data